Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueGross ProfitMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetRevenue - OtherShares OutstandingShares Outstanding
Ratios

Aclaris Therapeutics (ACRS) Other Gross PP&E Adjustments (2017 - 2025)

Aclaris Therapeutics has reported Other Gross PP&E Adjustments over the past 9 years, most recently at -$20.1 million for Q4 2025.

  • Quarterly results put Other Gross PP&E Adjustments at -$20.1 million for Q4 2025, down 51.21% from a year ago — trailing twelve months through Sep 2025 was $5.8 million (changed 0.31% YoY), and the annual figure for FY2025 was -$20.1 million, down 51.21%.
  • Other Gross PP&E Adjustments for Q4 2025 was -$20.1 million at Aclaris Therapeutics, down from $5.8 million in the prior quarter.
  • Over the last five years, Other Gross PP&E Adjustments for ACRS hit a ceiling of $6.3 million in Q3 2023 and a floor of -$20.1 million in Q4 2025.
  • Median Other Gross PP&E Adjustments over the past 5 years was $5.0 million (2022), compared with a mean of $396600.0.
  • Biggest five-year swings in Other Gross PP&E Adjustments: grew 27.18% in 2023 and later plummeted 51.21% in 2025.
  • Aclaris Therapeutics' Other Gross PP&E Adjustments stood at -$13.0 million in 2021, then decreased by 9.98% to -$14.3 million in 2022, then increased by 14.16% to -$12.3 million in 2023, then decreased by 8.27% to -$13.3 million in 2024, then plummeted by 51.21% to -$20.1 million in 2025.
  • The last three reported values for Other Gross PP&E Adjustments were -$20.1 million (Q4 2025), $5.8 million (Q3 2025), and $5.9 million (Q2 2025) per Business Quant data.